Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) FCF Margin (2018 - 2025)

10x Genomics' FCF Margin history spans 8 years, with the latest figure at 23.49% for Q4 2025.

  • For Q4 2025, FCF Margin rose 2922.0% year-over-year to 23.49%; the TTM value through Dec 2025 reached 20.24%, up 2118.0%, while the annual FY2025 figure was 20.24%, 2118.0% up from the prior year.
  • FCF Margin for Q4 2025 was 23.49% at 10x Genomics, down from 28.54% in the prior quarter.
  • Across five years, FCF Margin topped out at 28.54% in Q3 2025 and bottomed at 57.66% in Q4 2021.
  • The 5-year median for FCF Margin is 8.61% (2021), against an average of 9.72%.
  • The largest annual shift saw FCF Margin soared 10537bps in 2021 before it tumbled -4678bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 57.66% in 2021, then surged by 71bps to 16.65% in 2022, then surged by 35bps to 10.84% in 2023, then skyrocketed by 47bps to 5.74% in 2024, then skyrocketed by 510bps to 23.49% in 2025.
  • Per Business Quant, the three most recent readings for TXG's FCF Margin are 23.49% (Q4 2025), 28.54% (Q3 2025), and 8.46% (Q2 2025).